Source: Oncoscience. Unidade: FO
Assunto: NEOPLASIAS
ABNT
MACEDO, Mariana Petaccia de et al. RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. Oncoscience, 2022Tradução . . Disponível em: https://pubmed.ncbi.nlm.nih.gov/25859555/. Acesso em: 02 maio 2024.APA
Macedo, M. P. de, Melo, F. M. de, Ribeiro, J. da S., Mello, C. A. L. de, Begnami, M. D. F. de S., Soares, F. A., et al. (2022). RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. Oncoscience. Recuperado de https://pubmed.ncbi.nlm.nih.gov/25859555/NLM
Macedo MP de, Melo FM de, Ribeiro J da S, Mello CAL de, Begnami MDF de S, Soares FA, Carraro DM, Cunha IW da. RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions [Internet]. Oncoscience. 2022 ;[citado 2024 maio 02 ] Available from: https://pubmed.ncbi.nlm.nih.gov/25859555/Vancouver
Macedo MP de, Melo FM de, Ribeiro J da S, Mello CAL de, Begnami MDF de S, Soares FA, Carraro DM, Cunha IW da. RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions [Internet]. Oncoscience. 2022 ;[citado 2024 maio 02 ] Available from: https://pubmed.ncbi.nlm.nih.gov/25859555/